Interferon (IFN)-α is a type-I IFN known to exert a wide range of biological effects [1] . In addition to a potent antiviral activity against a wide range of viruses [2, 3] , this cytokine shows immunomodulatory activities, including maturation of antigen-presenting cells [4] or protection of T-cells from apoptosis [5] .
Interferon (IFN)-α is a type-I IFN known to exert a wide range of biological effects [1] . In addition to a potent antiviral activity against a wide range of viruses [2, 3] , this cytokine shows immunomodulatory activities, including maturation of antigen-presenting cells [4] or protection of T-cells from apoptosis [5] .
IFN-based therapies using polyethileneglycol derivatives (pegylated-interferon [PEG-IFN]) in combination with ribavirin (RBV) are the standard therapeutic option against HCV infection. The anti-HCV effect is achieved by the induction of antiviral proteins that directly inhibit HCV replication in hepatocytes, and by the modulation of regulatory proteins in immune cells that indirectly stimulate both innate and adaptive immunity against HCV [6] .
Large clinical trials, aimed to assess the efficacy and safety of IFN-or PEG-IFN-based schedules in HIV-HCV-coinfected populations, have demonstrated an additional capability of PEG-IFN to decrease plasma HIV RNA and to increase the percentage of CD4 + T-cells [3] ; however, the exact role of PEG-IFN/RBV treatment on the immune system is only partially characterized
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Marta Massanella 1 ) T-cells and T-cell receptor excision circles (TRECs) [7] , but this notion is controversial [8] . Among CD8 + T-cells, although a reduction on HLA-DR + cell number and the frequency of CD38 + cells has been described [8, 9] , little information exists on the mechanisms and the relevance of these changes.
Changes in cell subsets and activation status induced by PEG-IFN-α2a/RBV on T-cells might be relevant for both HCV and HIV replication. For HCV, it has been reported that phenotypic changes in HCV-specific CD8 + T-cells reflect the outcome of PEG-IFN-α2a/RBV treatment [10] . However, the potential effect of changes in other activation markers, such as CD38, HLA-DR or the role of CD4 + T-cells, which seem to be essential in maintaining successful memory CD8 + T-cell responses, are unknown. For HIV, it is clearly established that responses to highly active antiretroviral therapy (HAART) are highly dependent on both de novo CD4 + T-cell production and immune hyperactivation [11] [12] [13] . 
CD45RO
+ population responsible for this prediction [15] .
To better define the effect of two PEG-IFN-α2a/RBV dosages on T-cells from HIV-HCV-coinfected patients, we have monitored different parameters that define CD4 + T-cell production and CD8 + T-cell activation. Our data suggest a different modulation of CD4 + and CD8 + T-cell subsets by PEG-IFN-α2a/RBV in vivo. In particular, CD8 + T-cells expressing HLA-DR and/or CD45RO are selectively reduced in peripheral blood during treatment. By contrast, an up-regulation of CD38 was observed in memory CD4 + T-cells and in all CD8 + T-cell subsets. Small differences in the initial CD4 + T-cell decay were associated with the dose of PEG-IFN-α2a/ RBV administered, whereas changes in absolute naive CD4 + T-cell counts, but no absolute counts or activation phenotype of CD8 + T-cells, were associated with sustained virological response (SVR).
Methods
Patients
A total of 22 patients were selected at the University Hospital Germans Trias i Pujol (Barcelona, Spain) from among those included in the multicentre trials COR-AL-1 and CORAL-2. All patients gave informed consent to participate in the study. The CORAL-1 study compared the efficacy and safety of an induction dose of 270 µg/week of PEG-IFN-α2a for 4 weeks followed by the standard dose (180 µg/week) for 44 weeks versus the standard dose of PEG-IFN-α2a for 48 weeks. RBV was given at a dosage of 1,000-1,200 mg/day during the 48 weeks of therapy in both treatment arms [16] . The CORAL-2 trial compared the efficacy and safety of an induction dose of 270 µg/week of PEG-IFN-α2a plus 1,600 mg of RBV for 4 weeks followed by the standard dose of PEG-IFN-α2a plus 1,000-1,200 mg of RBV for 44 weeks versus the standard dose of PEG-IFN-α2a plus 1,000-1,200 mg of RBV for 48 weeks in patients with HCV genotype 1 or 4.
Selected patients were mostly on HAART (20 of 22) with protease inhibitor-or non-nucleoside reverse transcriptase inhibitor-based regimens or both (9, 8 and 3 patients, respectively). Patients had CD4 + T-cell count >300 cells/µl and plasma HIV RNA<50 copies/ml for more than 48 weeks, and completed at least 24 weeks of therapy. Patients were classified according to PEG-IFN-α2a dosage in patients receiving PEG-IFN-α2a 270 µg/week for 4 weeks plus RBV 1,000-1,600 mg/ day followed by PEG-IFN-α2a 180 µg/week plus RBV 1,000-1,200 mg/day for 44 weeks (n=11, high dose group) and patients receiving PEG-IFN-α2a 180 µg/ week plus RBV 1,000-1,200 mg/day for 48 weeks (n=11, standard dose group).
Patients were followed in an outpatient regimen for adverse events, tolerance and adherence. HCV Virological response was analysed at two time points. Early virological response (EVR) was defined as undetectable HCV RNA or a decrease of ≥2 log in HCV RNA at week 12. SVR was measured at week 72 (24 weeks after treatment cessation) and defined by undetectability of plasma HCV RNA. Given the better response associated with genotype 3 [3, 17] , the four patients bearing HCV from this genotype (all achieving SVR) were excluded from the final analysis (three patients from the standard and one from the high PEG-IFN-α2a/RBV dose arm).
Analysis of lymphocyte subsets
To analyse activation markers in peripheral blood we used cryopreserved peripheral blood mononuclear cells (PBMCs), a procedure that has been validated previously [18] . Briefly, aliquots of frozen PBMCs were rapidly thawed and washed twice in phosphate-buffered saline (PBS) containing 10% fetal calf serum (FCS). Cells were stained with propidium iodide 10 µg/ml for 15 min and analysed to evaluate cell death during the freezing/thawing process. Samples with >15% death cells were not included in the analysis.
Different combinations of antibodies were used to characterize lymphocyte subsets. Combination 1 was designed to evaluate CD4 + T-cell subsets and contained CD45RA-fluorescein isothiocyanate (FITC), CD31-phycoerythrin (PE), CD38-peridinin chlorophyll protein (PerCP), CD3-allophycocyanin (APC)-indocyanine 7 (Cy7), CD4-APC and CD8-PE-Cy7 antibodies. Combination 2 was designed to evaluate the activation of CD8 + T-cells and contained HLA-DR-FITC, PD-1-PE, CD38-PerCP, CD45RO-APC, CD3-APC-Cy7 and CD8-PE-Cy7 antibodies. Controls with combinations of CD3-APC-Cy7, CD4-APC and CD8-PE-Cy7 antibodies were performed for all samples. All antibodies were from Becton Dickinson (San Jose, CA, USA).
For staining with antibodies, 200,000 cells were incubated for 20 min at room temperature with the different combinations in V-bottom 96-well plates. After incubation, cells were washed in PBS and resuspended in PBS containing 1% formaldehyde. Acquisition of flow cytometry data was performed on a LSR II Flow Cytometer (Becton Dickinson) coupled with an HTS loader. At least 30,000 lymphocytes were collected for each sample. Analyses were performed with FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Quantitative analysis of CD38 expression
An additional combination of antibodies was designed to quantify the number of cell surface molecules of CD38 in different lymphocyte subsets (combination 3). This combination contained CD38-PE Quantibrite, CD45RO-APC, CD3-APC-Cy7, CD4-PerCP and CD8-PE-Cy7 antibodies, all from Becton Dickinson. In parallel with stained samples, Quantibrite beads (Becton Dickinson) were run for each experiment. Quantification of the number of CD38 molecules was performed as recommended by the manufacturer.
Statistical analyses
Analyses of longitudinal changes in lymphocyte absolute counts and relative percentages of each subset were performed using the Wilcoxon rank-sum test. Comparisons between patients grouped according to PEG-IFN-α2a/ RBV dosage or virological response were performed using the Mann-Whitney U test.
Results
Effect of PEG-IFN-α2a/RBV on absolute lymphocyte counts
As previously reported [3] , PEG-IFN-α2a/RBV induced in treated patients (n=22) a significant decrease of the number of circulating total lymphocytes and T-cells (P=0.0006 and P=0.004 at week 48, respectively) that returned to baseline levels after treatment cessation ( Figure 1A and 1B). This transient decrease significantly affected both CD4 + T-cells and CD8 + T-cells (P=0.0004 and P=0.0004 at week 48, respectively; Figure 1C and 1D), although the loss of CD8 + T-cells was more pronounced, resulting in transient increases in the percentage of circulating CD4 + T-cells (P=0.0007 at week 48; Figure 1E ). Overall, the dose of PEG-IFN-α2a received during the first 4 weeks of treatment (180 or 270 µg/ week) had little effect in the time course of the parameters monitored. However, the initial lymphopaenia was more pronounced in patients receiving high doses of PEG-IFN-α2a, and this finding was specifically associated with a significant reduction in the absolute CD4 + T-cell counts at week 4 (P=0.001; Figure 1F ). As the loss of CD8 + T-cells was similar in both dose groups, the short-term increase in the percentage of CD4 + T-cells was significant only in the standard PEG-IFN-α2a/RBV dose group (P=0.03; Figure 1F ). Figure  2A and 2B) that were absent in the standard dose group. As there was a similar reduction in CD45RA + and CD45RO + cells, the percentages of these populations remained unchanged, although a trend towards a reduced percentage of CD45RA + cells was observed at week 48, which was more pronounced in the high dose group (MM et al., data not shown). A similar finding has been previously reported and related to a reduced thymic output measured by TRECs content in PBMCs [7] . To address whether the effect of PEG-IFN-α2a/RBV on thymic production could account for a decreased naive T-cell production, we analysed the absolute counts and the percentage of CD31 + CD45RA + CD4 + T-cells ( Figure 2C ). Although CD31 expression does not completely exclude proliferating cells [19] , CD31 + CD45RA + CD4 + T-cells appear to contain 90% of TRECs and might be used as a surrogate marker for the recent thymic emigrant population [20, 21] . A significant reduction in the percentage of these cells at week 48 was observed in the high PEG-IFN-α2a/RBV group (P=0.008; P=0.19 in the standard dose group). However, absolute values were fully recovered after treatment cessation in the high PEG-IFN-α2a/RBV group (146 ±142 cells/µl at week 72 versus 159 ±137 cells /µl at baseline). Furthermore, no significant differences were observed through the follow-up in the percentage of CD31 -cells in CD45RA + CD4 + T-cells ( Figure 2D ), a surrogate marker of peripheral expansion of naive cells [21] .
Effect of PEG-IFN-α2a/RBV on CD4 + T-cell subsets
The expression of CD38 in both the CD45RA + and the CD45RO + CD4 + T-cell subsets was also evaluated. Although naive cells showed constant percentages of CD38 + cells, a significant increase was observed in the CD45RO + CD4 + T-cell population (P=0.0026 at week 48) that reverted at week 72 ( Figure 2E and 2F) . Figure 3A and 3B). However, the reduction of CD45RO + cells was higher, leading to significantly decreased percentages of circulating CD45RO + CD8
+ T-cells (P=0.0078 at week 48; Figure 3C ). A significant reduction was also observed in the percentage of HLA-DR + CD8 + T-cells (P<0.0001 at week 24, but P=0.27 at week 48; Figure 3D ). Unexpectedly, these changes were concomitant to an increase in the percentage of CD38 + cells, which was not significant in the CD45RA + subset (P=0.2 at week 48; Figure 3E ) but highly significant in the CD45RO + CD8 + T-cell subset (P=0.0012 at week 48; Figure 3F ). this possibility, we quantified the expression of CD38 in both CD45RA + and CD45RO + subsets of CD4 + and CD8 + T-cells. Figure 4C shows unchanged levels of CD38 in naive CD4 + T-cells and a small but significant increase in memory CD4 + T-cells (P=0.0073 at week 48; Figure 4D ). By contrast, both CD45RA + and CD45RO + CD8 + T-cells increased the levels of cell-surface-expressed CD38 (P=0.0117 and P=0.0024 at week 48, respectively), although the increase was higher in memory cells (Figure 4E and 4F) . As a whole, these data suggest that PEG-IFN-α2a/RBV treatment is able to up-regulate CD38 expression in CD45RO + cells and that this effect compensates for the selective removal of CD45RO + and HLA-DR + CD8 + T-cells from peripheral blood to maintain the level of double-positive CD8 + T-cells. Although changes in CD38 expression in CD8 + T-cells were not statistically different in high and standard PEG-IFN-α2a/RBV dose groups, they showed a different kinetics. Standard doses induced a sustained increase during the treatment period, whereas high doses induced a marked initial increase that was maintained until treatment cessation.
Association of changes in activation markers with clinical outcome and HAART treatment
The response to treatment was assessed by monitoring the short-term decay in plasma HCV RNA at week 12 and the SVR at week 72. To avoid the bias induced by the sensitivity of the different HCV genotypes to treatment, this analysis was performed in patients bearing genotype 1 (n=15) or genotype 4 (n=3) viruses. From these patients (n=18), nine achieved EVR (five from the standard dose group and four from the high dose group). By contrast, only six patients achieved SVR (four from the standard dose group and two from the high dose group). The remaining 12 patients showed HCV rebound after EVR (3 patients) or were poor responders (9 patients). No significant association between PEG-IFN-α2a/RBV dose and EVR or SVR was observed.
Although the number of patients included in our study limits the analysis of the relationships between alterations in T-cell subsets and virological responses, we observed higher decreases of absolute CD4 + and CD8 + T-cell counts in responder patients. However, these changes did not reach statistical significance, except for the decrease of CD45RA + and CD45RA + CD31 + CD4 + T-cells (P=0.01 and P=0.02, respectively), which reflected in part the higher baseline values of these cells in responder patients. Similar trends were observed when patients were grouped according to EVR response (defined as undetectable viral load at week 12). Conversely, no differences in the effect of PEG-IFN-α2a/RBV treatment on T-cell subsets, CD38 expression or virological response were observed when patients were grouped according to the HAART background (protease inhibitor-or nonnucleoside reverse transcriptase inhibitor-based), suggesting that, in our limited study, anti-HIV therapy does not influence PEG-IFN-α2a/RBV treatment.
Discussion
Our data expand previous reports describing the effect of PEG-IFN-α2a on lymphocyte subsets and HCVspecific CD8
+ T-cells [3, 7, 10] and suggest that CD8 + T-cells, little changes were observed in the composition of this compartment. However, these small changes might be relevant. In particular, the level of naive CD4 + T-cell production has been shown to be a key factor of CD4 + T-cell recovery during anti-HIV therapy [11] , and our data point to a relationship between the removal of naive CD4 + T-cells from the periphery and long-term HCV suppression during PEG-IFN-α2a/ RBV treatment. The relevance of the naive CD4 + T-cell compartment is also highlighted by the finding that its recovery has been reported to be incomplete in some HIV-HCV-coinfected patients undergoing a similar treatment schedule [7] ; however, absolute numbers of both naive and memory CD4 + T-cells were fully recovered in our patients, irrespective of the PEG-IFN-α2a/ RBV dose, after treatment cessation. Only a small decrease in the percentage of the recent thymic emigrant CD4 + T-cell population (CD45RA + CD31 + ) [20] and a non-significant increase in the percentages of CD31 -cells in the CD45RA + CD4 + T-cell pool (a potential surrogate marker of peripheral expansion of naive cells) [21] were observed at week 48 in patients receiving high PEG-IFN-α2a/RBV doses, which were recovered at week 72. Given that the recovery of CD45RA + CD4
+ T-cells is observed in the absence of significant changes in peripheral proliferation, our data suggest that PEG-IFN-α2a/RBV did not induce irreversible damage of thymic function. No relevant information could be retrieved from the analysis of the memory CD4 + T-cell compartment, in which only an increase in the expression of CD38 was observed, probably associated with up-regulation of this antigen as discussed below. A relevant consequence of CD4 + T-cell reduction in peripheral blood is the risk of opportunistic infections. There is limited data about the efficacy and safety of IFNbased therapies in HIV-HCV-coinfected patients with severe immunosuppression. A recent study has reported the development of two episodes of opportunistic infections in patients starting IFN therapy with a CD4 + cell count <250 cells/µl [22] , suggesting the need of intensive primary prophylaxis in patients with a CD4 + T-cell count <200 cells/µl during IFN-based therapy, irrespective of HIV viral load. [13, 15] . These data are in contrast with the recently described reduction in CD38 expression induced by PEG-IFN treatment that suggests a reduction in immune activation [9] . In our study, several lines of evidence suggest that increased expression of CD38 is associated with a specific up-regulation of this molecule rather than to an increased level of immune activation. First, CD38 promoter show IFN responsive sequences and has been reported to be upregulated by type I IFN in monocytes [23] . Similarly, in vitro incubation of PBMCs from HIV-infected patients with recombinant IFN-α2a leads to CD38 up-regulation [5] . Paralleling our in vivo observation with the latter in vitro study, a higher induction of CD38 expression was observed in CD8 + T-cells compared with CD4 + T-cells [5] . Finally, CD38 is coexpressed in HLA-DR + CD8 + T-cells, showing correlated expression in double-positive cells (HLA-DR bright cells showing the highest levels of CD38 expression). Therefore, selective removal of HLA-DR + cells should result in lower, rather than increased, levels of CD38 expression. Furthermore, also in in vivo settings, type-I IFN, produced by plasmacytoid dendritic cells, has been postulated to contribute to phenotypic T-cell activation during HIV infection [24] .
The relevance of CD38 up-regulation is still unclear; CD38 has been shown to be a fully active NADase in HIV-infected individuals [25] , to display ADP ribosyl cyclase and hydrolase activities [26] , and to be the ligand of CD31 during lymphocyte transmigration [27] .
Although this latter possibility might explain increased disappearance of activated CD8 + T-cells from peripheral blood in our patients, no clear correlation was observed between increased CD38 expression and removal from the periphery and the relevance of the CD38-CD31 interaction in vivo is still controversial [28] . A more plausible explanation points to the enzymatic activity of CD38, which might be necessary for recovery of purine metabolites released in tissues with increased rates of cell death. In particular, CD38 might be important for efficient removal of extracellular NAD, which is known to modulate different immune functions, including phagocytosis and regulatory T-cells [29] [30] [31] . Regardless, the analysis of the association of increased CD38 expression did not show significant effect on clinical outcome in the patients studied. Similarly, no evidence for a dose-response effect was observed when the groups receiving different doses of PEG-IFN-α2a/ RBV were analysed, although changes in CD38 expression appeared to follow different kinetics.
In conclusion, our data suggest a potent effect of PEG-IFN-α2a/RBV on CD8 + T-cells, characterized by selective disappearance of memory-activated cells and increased expression of CD38. The effect on CD4 + T-cells was quantitatively lower, but important enough to influence SVR. The exact role of both CD38 expression and CD4 + T-cell help on anti-HCV activity of PEG-IFN-α2a/RBV, in particular on HCV-specific CD8 + T-cells, warrants further study in larger cohorts.
